Aspen Neuroscience, a pioneering force in regenerative medicine, has received clearance from the U.S. FDA for its Investigational New Drug (IND) application for ANPD001. ANPD001 is a novel autologous (“self-derived”) cell therapy that has the potential to treat Parkinson’s Disease by replenishing lost dopamine neurons. This green light from the FDA propels Aspen Neuroscience into historic territory, initiating a clinical trial for ANPD001 in human patients. [Read more…]
Celularity – Big Bucks, Billionaire Investors, Bold Dreams
Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]
I Dream of Genome: Why Is Gene Sequencing Important?
There’s no one exactly like you.
You know this is true, but it’s actually scientifically accurate. There is no one who has the exact same DNA as you do, though everyone in the world comes close. In fact, research shows that human beings share a genetic makeup that is 99.9% identical. [Read more…]
Gene & cell therapy manufacturing specialist Ascend launches with over $130M of funding as expert teams merge
LONDON, May 9, 2023 — Ascend Gene & Cell Therapies (Ascend), a specialist company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, announces that it has launched as a facilitator for gene therapy companies to help translate product ideas into viable clinical programs.
Ascend offers process development, clinical manufacturing, and analytical and regulatory support for biotech companies working in advanced modalities requiring flexible CMC services. Originally founded by Monograph Capital, Ascend has raised a total of $132.5M, most recently completing a Series A fundraise led by Abingworth and Petrichor, supported by DCVC Bio, 4BIO Capital, Cathay Health, Deerfield Management, Digitalis Ventures and Ajinomoto Co., Inc. [Read more…]
A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology
SHANGHAI — On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO” or “the Company”), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world. [Read more…]
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 63
- Next Page »